echosens
Echosens is a Paris-based private medical device company that develops and distributes FibroScan, the non-invasive gold-standard device for liver fibrosis and steatosis assessment using proprietary VCTE elastography, sold across 127+ countries to hepatologists, hospitals, and pharmaceutical clinical trial sponsors.
- Company typePrivate
- Founded1999
- HeadquartersParis, France
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What echosens does
Echosens SA is a Paris-headquartered, privately held medical device company founded in 1999 that has pioneered non-invasive liver diagnostics for over 25 years. Its flagship product, FibroScan, is built on proprietary Vibration Controlled Transient Elastography (VCTE), which measures liver stiffness (fibrosis) and steatosis (fat) via Controlled Attenuation Parameter (CAP) in under 10 minutes at the point of care, eliminating the need for invasive liver biopsy in many clinical scenarios. The technology is supported by 6,000+ peer-reviewed publications and 250+ international clinical guidelines, and FibroScan is recognized as the global reference standard for non-invasive liver assessment across 127+ countries.
The product portfolio spans multiple FibroScan hardware variants (630 Expert, 530 Compact, PRO, Q, HANDY, BOX), the next-generation Guided VCTE technology, the cloud-based Liver Health Management (LHM) platform with clinical decision support, FibroScan-based diagnostic scores (FAST, Agile 3+, Agile 4), the myFibroScan patient portal, and the LHM Research clinical trial services platform for pharmaceutical MASH/NASH drug development. Revenue is generated through hardware device sales, software subscriptions and platform services, post-warranty service and maintenance contracts, and pharma clinical trial services.
Echosens serves hepatologists, gastroenterologists, hospitals, hepatology centers, primary care and endocrinology practices (for metabolic liver screening), and pharmaceutical companies running MASH/NASH clinical trials. Distribution is via a global certified distributor network supplemented by direct sales to major accounts, with dedicated regional service infrastructure in North America, EMEA, APAC, Latin America, and Africa. The company is led by CEO Romain Baujard and operates without any disclosed parent company, private equity backing, or public listing despite 25+ years of independent operation.
echosens firmographics
Firmographics- Name
- echosens
- Legal name
- Echosens SA
- Website
- https://echosens.us
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Short description
- Echosens is a Paris-based private medical device company that develops and distributes FibroScan, the non-invasive gold-standard device for liver fibrosis and steatosis assessment using proprietary VCTE elastography, sold across 127+ countries to hepatologists, hospitals, and pharmaceutical clinical trial sponsors.
- Ownership category
- akta.pro rank
echosens industry classification
Industry- Product category
- Medical Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ultrasound & Echography Systems (HLAHABAD)
- akta.pro secondary industry
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where echosens is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
echosens business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- FibroScan Medical Device Sales: Sale of FibroScan hardware devices including FibroScan 630 Expert, FibroScan 530 Compact, FibroScan PRO, FibroScan Q, FibroScan HANDY, and FibroScan BOX. Revenue from initial device acquisition with associated software licenses. New products come with 12-month warranty plus 2 months for logistics and installation.
- Software Subscriptions and Platform Services: Cloud-based Liver Health Management (LHM) platform subscription services, myFibroScan patient portal access, and FibroScan-based Scores biomarker services. Annual subscription model for platform access and data management.
- Service and Maintenance Contracts: Post-warranty service contracts, probe calibration services (explicitly separate from warranty), and technical support services. Replacement parts provided under 12-month coverage.
- Clinical Trial Services (LHM Research): Specialized services for pharmaceutical clinical trials including standardized examination data collection, quality control, and regulatory-grade reporting for drug development programs.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels8 records
echosens product offering
Product offeringCore offering
Echosens develops, manufactures, and sells FibroScan, a non-invasive medical device that uses proprietary Vibration-Controlled Transient Elastography (VCTE) technology to measure liver stiffness (fibrosis) and steatosis (fat) for the diagnosis and monitoring of chronic liver disease. The company complements its hardware devices with a software ecosystem including the Liver Health Management (LHM) cloud platform, FibroScan-based diagnostic Scores (FAST, Agile 3+, Agile 4), the myFibroScan patient portal, and the LHM Research clinical trial solution for pharmaceutical sponsors.
Product overview
Echosens offers FibroScan®, the gold standard non-invasive solution for liver disease assessment, delivered through a portfolio of hardware devices and software platforms. The core product line includes FibroScan® devices in multiple variants (630 Expert, 530 Compact, PRO, Q, HANDY, BOX) that use proprietary VCTE® (Vibration-Controlled Transient Elastography) technology to measure liver stiffness and controlled attenuation parameter (CAP) for fat assessment. The ecosystem includes Liver Health Management (LHM) cloud platform for clinical decision support, FibroScan®-based Scores (Fast™, Agile 3+, Agile 4) for enhanced diagnostic biomarkers, myFibroScan patient portal, LHM Research for pharma clinical trials, and Guided VCTE® as the next-generation examination technology. This integrated portfolio supports the entire liver disease diagnostic pathway from screening to monitoring across 127+ countries.
Differentiator
Problem solved
Functional benefit
Brands
- FibroScan: The company's flagship non-invasive liver elastography device for assessing liver fibrosis and steatosis
- VCTE (Vibration Controlled Transient Elastography)
- Liver Health Management (LHM)
- myFibroScan
- LHM Research
- FibroMeter
- FAST Score
- Agile 3+
- Agile 4
- Guided VCTE
- Echosens Academy
Products and services
- FibroScan 630 Expert
Quantifiable outcome
- 6,000+ peer-reviewed publications support FibroScan/VCTE clinical performance
- +3 more outcomes
Companies that use echosens
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
echosens technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature8 records
echosens partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights6 records
echosens competitors and assessment
Company assessmentEmerging players
- Genfit: Biotech with a diagnostic biomarker franchise (NIS4) for NASH/MASH identification, representing a blood-based alternative to FibroScan for patient screening and stratification.
- Samsung Medison: Subsidiary of Samsung offering premium ultrasound with elastography (e.g., RS85 with S-Shearwave), competing with FibroScan at the high end of hospital imaging suites.
- Mindray: Lower-cost ultrasound vendor adding elastography capabilities to its platform, increasing price competition for non-invasive liver assessment, particularly in cost-sensitive markets.
- Perspectum: Developer of LiverMultiScan, an MRI-based multiparametric liver assessment, providing an alternative non-invasive diagnostic for MASLD/MASH and competing for the same clinical decision budgets.
- Resonance Health: Provides MRI-PDFF-based liver fat quantification, already cited by Echosens itself as a reference standard for CAP, representing a credible non-invasive alternative in research and pharma settings.
Direct peers
- Siemens Healthineers: Major imaging incumbent whose ACUSON ultrasound family includes shear wave elastography for liver fibrosis assessment, directly competing with FibroScan in hospital radiology and hepatology departments.
- GE HealthCare: Ultrasound leader offering 2D shear wave elastography on LOGIQ platforms, providing clinicians a 'good enough' liver stiffness measurement bundled into broader ultrasound fleet purchases.
- Canon Medical Systems: Aplio i-series ultrasound systems offer shear wave elastography for liver fibrosis, providing another hospital-grade alternative to VCTE-based FibroScan exams.
- Philips: Operates in liver imaging through its EPIQ and Affiniti ultrasound systems with ElastPQ quantification, competing for the same hospital budgets as FibroScan for liver assessment.
Others
- Clario: Clinical trial technology and imaging CRO with deep NASH/MASH trial infrastructure. Competes for pharma-services spend alongside Echosens' LHM Research, particularly for imaging endpoint management in liver trials.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
echosens social profiles
Digital presenceechosens financial estimates
Financial estimateRevenue estimate
Valuation estimate
echosens leadership team
Management profileNumber of profiles
Profiles1 record
echosens funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
echosens M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about echosens
What does echosens do?
Echosens develops, manufactures, and sells FibroScan, a non-invasive medical device that uses proprietary Vibration-Controlled Transient Elastography (VCTE) technology to measure liver stiffness (fibrosis) and steatosis (fat) for the diagnosis and monitoring of chronic liver disease. The company complements its hardware devices with a software ecosystem including the Liver Health Management (LHM) cloud platform, FibroScan-based diagnostic Scores (FAST, Agile 3+, Agile 4), the myFibroScan patient portal, and the LHM Research clinical trial solution for pharmaceutical sponsors.
Is echosens a public or private company?
echosens is a private company. It is classified as unknown and is currently operating.
When was echosens founded?
echosens was founded in 1999.
Where is echosens based?
echosens is headquartered in Paris, France, in the Europe region.
How does echosens make money?
Four revenue lines are on record. FibroScan Medical Device Sales are the primary driver. The others are software Subscriptions and Platform Services, service and Maintenance Contracts and clinical Trial Services (LHM Research).
Who are echosens's main competitors?
Emerging players on record are Genfit, Samsung Medison, Mindray, Perspectum and Resonance Health. Direct peers are Siemens Healthineers, GE HealthCare, Canon Medical Systems and Philips. Clario is listed as an others.
Does echosens have an API?
No public API is recorded for echosens.
What industry is echosens in?
echosens's product category is Medical Diagnostic Devices. Its primary akta.pro industry code is HLAHABAD, Ultrasound & Echography Systems, with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 334510 and its SIC code is 3841.